---
title: "Opthea to Delist from Nasdaq, Focuses on ASX and Australian Market"
description: "Opthea Limited (AU:OPT) has announced its voluntary delisting from the Nasdaq Stock Market, while retaining its listing on the Australian Securities Exchange (ASX). This decision aims to streamline op"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263404637.md"
published_at: "2025-10-30T01:27:59.000Z"
---

# Opthea to Delist from Nasdaq, Focuses on ASX and Australian Market

> Opthea Limited (AU:OPT) has announced its voluntary delisting from the Nasdaq Stock Market, while retaining its listing on the Australian Securities Exchange (ASX). This decision aims to streamline operations and reduce costs, focusing on the Australian market to enhance shareholder value. The company will continue its American Depositary Receipt program for U.S. investors in the OTC market. The latest analyst rating for Opthea stock is a Sell, with a price target of A$0.05. Current market cap stands at A$738.8M.

The latest announcement is out from Opthea ( (AU:OPT) ).

Opthea Limited has announced its decision to voluntarily delist from the Nasdaq Stock Market while maintaining its listing on the Australian Securities Exchange (ASX). This strategic move is aimed at streamlining operations, reducing costs, and focusing on the Australian market to enhance long-term shareholder value. The company plans to continue its American Depositary Receipt program to facilitate trading for U.S. investors in the OTC market, aligning its structure with operational priorities.

The most recent analyst rating on (AU:OPT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.

**More about Opthea**

Opthea Limited is a biopharmaceutical company focused on developing novel therapies to treat diseases mediated by Vascular Endothelial Growth Factors (VEGF) C and/or D.

**Technical Sentiment Signal:** Sell

**Current Market Cap:** A$738.8M

### Related Stocks

- [OPT.AU - Opthea Limited](https://longbridge.com/en/quote/OPT.AU.md)
- [OPT.US - Opthea](https://longbridge.com/en/quote/OPT.US.md)
- [OPTEY.US - OPTHEA LIMITED SPON ADR EACH REP 8 ORD SHS](https://longbridge.com/en/quote/OPTEY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 最高法院推翻了特朗普的关税政策。接下来是艰难的退款工作 | 最高法院已宣布特朗普总统的主要关税无效，这引发了对已经征收的 1330 亿美元非法进口税的质疑。公司正在寻求退款，但处理这些退款的流程仍不确定 | [Link](https://longbridge.com/en/news/276504104.md) |
| Baader Bank Aktiengesellschaft 出售了 54,069 股纳斯达克公司（Nasdaq, Inc.）的股票，股票代码为$NDAQ | Baader Bank Aktiengesellschaft 在第三季度将其在纳斯达克公司的持股减少了 86.5%，出售了 54,069 股，剩余 8,450 股，价值 74.5 万美元。其他机构投资者也调整了他们在纳斯达克的持仓。该股票开 | [Link](https://longbridge.com/en/news/275735016.md) |
| 在澳大利亚证券交易所科技板块遭遇抛售和技术性下跌趋势后，重新审视 Technology One (ASX:TNE) 的估值 | Technology One（ASX:TNE）面临压力，因为 ASX IT 行业出现抛售，其股价为 21.30 澳元，反映出 30 天内回报率为 21.86%，年初至今下降 23.55%。分析师已将目标价修订为 34.87 澳元，表明该股票 | [Link](https://longbridge.com/en/news/276075545.md) |
| Euronext 奥斯陆证券交易所 - Parc Bidco AS - 已收到债券上市的申请 | Euronext Oslo Børs 已收到关于 ISIN NO0013478800 的申请，以便将其纳入股票交易所上市。市场滥用法规（MAR）自申请提交之时起生效，包括发行人的信息披露义务 | [Link](https://longbridge.com/en/news/276064747.md) |
| Fortifai 以每股 0.30 澳元的发行价成功筹集了 500 万澳元 | Fortifai Ltd：以每股 0.30 澳元的发行价筹集 500 万澳元 | [Link](https://longbridge.com/en/news/276400352.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.